Partner David Rosen was quoted in an Inside Health Policy article on January 22, 2014 titled “Generic Drug Industry Prioritizes Challenge to New Labeling Rule in 2014.” The article discusses the top priority for the generic drug industry in 2014 which will be combating a new regulation aimed at requiring generic drugmakers to make labeling changes to reflect new safety information. Rosen was quoted saying, “I think it’s going to be a pretty big deal.”
People
Related News
11 February 2025
In the News
Foley Attorneys on CFPB Shutdown – Industry in 'wait-and-see mode'
Foley & Lardner LLP attorneys Christi Lawson, Natasha Dempsey, and Whitney Nicholas assessed the Trump administration's curtailment of the Consumer Financial Protection Bureau (CFPB) in the Newsweek article, "What CFPB Shutdown Means for Junk Fees."
11 February 2025
In the News
Justus Britt Assesses Suspension of National EV Infrastructure Program
Foley & Lardner LLP senior counsel Justus Britt assessed the Trump administration's suspension of the National Electric Vehicle Infrastructure (NEVI) program in the Law360 article, "EV Charging Supply Chain In Limbo Amid Funding Freeze."
11 February 2025
In the News
Foley Featured as Law360 Health Care Practice Group of the Year
Foley & Lardner LLP is featured in Law360 for the firm's recognition as a 2024 Health Care Practice Group of the Year.